Score Breakdown
Trash.
Aehr Test Systems is a speculative micro-cap trading at an absurd $2.2B market cap (~49x TTM sales) on the promise that AI burn-in testing will become a massive growth driver. While the $50M+ backlog and record bookings are real, the company is currently burning cash, losing money, has exhausted its ATM facility, carries bloated inventory (4x quarterly revenue), and faces intense customer concentration risk. Even in an optimistic scenario where FY2027 revenue reaches $95M with 15% FCF margins (~$14M FCF), the stock trades at >150x forward FCF. The valuation requires near-flawless execution on AI ramp, sustained 30%+ revenue growth for years, and significant margin expansion — all while competing against larger, better-capitalized semiconductor test incumbents. At current prices, the stock is priced for perfection in a business that has delivered consistent disappointment over the past 18 months. This is a compelling short candidate.
Negative cash flow. Can't value it.
Some yellow flags.
Minimal.
Neutral.
Plenty of cash.
Significant shorts.
Below average.
🐻 Why Bears Hate It
The bear case centers on an extreme valuation disconnect; despite a market cap exceeding $2 billion, the company is struggling with declining year-over-year revenue and consistent GAAP losses. Analysts have noted a 'hold' consensus with a price target of $16.50, implying a potential downside of nearly 50% from recent trading levels. Furthermore, the bull case relies heavily on 'effective backlog' and future AI orders that have yet to translate into sustained profitability (Value The Markets, Stocktwits).
🔍 What's In The SEC Filings
The company is survival-funding operations through aggressive equity dilution while maintaining a questionable $21.9 million deferred tax asset despite mounting losses.
Total exhaustion of At-The-Market (ATM) equity offering to fund operations.
“The March 2026 sales fully utilized the remaining capacity under the current ATM offering program.”
The company used an ATM program to raise approximately $40 million in gross proceeds between November 2025 and March 2026 to offset a $5.1 million operating cash burn and maintain liquidity as revenues cratered.
Massive revenue contraction and extreme customer volatility.
“Revenue [for the 3 months ended Feb 27, 2026] was $10,313 [compared to] $18,307 [for the prior year].”
Quarterly revenue declined 43.7% year-over-year. One major customer (Customer E) plummeted from 45.3% of 9-month revenue in 2025 to less than 10% in 2026, signaling a loss of anchor clients.
Aggressive retention of Deferred Tax Assets (DTAs) without valuation allowance despite losses.
“management continues to reassess at each reporting date whether sufficient positive evidence exists to support realization of the U.S. DTAs.”
Management is carrying $21.9M in DTAs based on a 2024 release of valuation allowance, yet the company has incurred $11.2M in pre-tax losses over the last 9 months, creating a high probability of a future multi-million dollar write-down.
Bloated inventory levels relative to current sales run-rate.
“Inventories consisted of... $41,162 [thousand].”
With current quarterly revenue at $10.3M, the $41.2M inventory balance represents a 4x revenue-to-inventory ratio (12 months of sales), suggesting high risk of obsolescence or overvaluation.
Loss of intellectual property infringement case in China.
“In December 2025, the Company received a first-instance judgment from the Suzhou Intermediate People’s Court... which dismissed the Company’s claims.”
The company failed to establish infringement in its patent case against Semight in China; while under appeal, this threatens their competitive position and ability to protect margins in the Asian market (which accounts for 50% of revenue).
Intrinsic value is significantly lower than reported book value; a mandatory valuation allowance on DTAs and probable inventory impairments would likely wipe out over $30M (approx. 22%) of total shareholders' equity.
The company's restructuring charges for facility consolidation and workforce reductions suggest management is in a defensive 'shrink-to-survive' mode rather than an expansionary phase.